Evolus, Inc.
DB:EVL 株式レポート
Evolus マネジメント 主要情報 CEO給与比率 6.1% CEO在任期間 6.5yrs CEOの所有権 n/a 経営陣の平均在職期間 3yrs 取締役会の平均在任期間 6.5yrs
経営陣の近況
Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee Jul 01
President recently sold €1.6m worth of stock Jun 10
President recently sold €190k worth of stock May 16
Evolus, Inc. Announces Board Changes Apr 04
President recently sold €1.2m worth of stock Mar 22
Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications Jan 05
すべての更新を表示
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.30 loss in 3Q 2023) Nov 08
Evolus, Inc. Provides Earnings Guidance for the Year 2024 Nov 07
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation Nov 01
Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.32 loss in 2Q 2023) Aug 02
Evolus, Inc. Raises Financial Guidance for the Full Year of 2024 Aug 01
Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee Jul 01
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products Jun 24
President recently sold €1.6m worth of stock Jun 10
Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting May 23
President recently sold €190k worth of stock May 16
Forecast breakeven date moved forward to 2025 May 09
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024 May 09
First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 1Q 2023) May 08
Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau Apr 18
Evolus, Inc. Announces Board Changes Apr 04
President recently sold €1.2m worth of stock Mar 22 Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million. Mar 11
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024 Mar 08
Full year 2023 earnings released: US$1.08 loss per share (vs US$1.33 loss in FY 2022) Mar 08
Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Feb 23
Evolus, Inc. Announces Earnings Guidance for 2024 Jan 17
Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications Jan 05
New minor risk - Shareholder dilution Dec 21
President recently sold €765k worth of stock Dec 11
New minor risk - Insider selling Nov 16
No longer forecast to breakeven Nov 09
Evolus, Inc. Raises Earnings Guidance for the Full Year 2023 Nov 08
Third quarter 2023 earnings released: US$0.30 loss per share (vs US$0.36 loss in 3Q 2022) Nov 08
Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau Nov 07
Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26
Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer Aug 22
President recently sold €139k worth of stock Aug 18
Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers Aug 09
New major risk - Negative shareholders equity Aug 04
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.42 loss in 2Q 2022) Aug 03
New major risk - Share price stability Jul 30
Evolus, Inc. Revises Revenue Guidance for the Year 2023 Jul 29
Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy Jun 30
Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R) Jun 23
First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.31 loss in 1Q 2022) May 10
Evolus, Inc. Provides Revenue Guidance for the Year 2023 May 10
Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023 May 06
Full year 2022 earnings released: US$1.33 loss per share (vs US$0.94 loss in FY 2021) Mar 09
Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance Jan 29
Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia Jan 24
Evolus, Inc. Provides Earnings Guidance for the Year 2023 Jan 19
Forecast to breakeven in 2025 Dec 31
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.36 loss per share (vs US$0.35 loss in 3Q 2021) Nov 10
Evolus, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 09
Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Independent Director recently bought €92k worth of stock Sep 07
Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022 Aug 31
Forecast to breakeven in 2024 Aug 04
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.30 loss in 2Q 2021) Aug 03
Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022 Aug 03
Insufficient new directors Aug 02
Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 20
Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau Jul 13
Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials Jun 04
Independent Director recently sold €132k worth of stock May 19 Evolus, Inc. Revises Earnings Guidance for the Year 2022 May 12
First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.17 profit in 1Q 2021) May 11
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau Apr 01 Evolus, Inc. Reaffirms Revenue Guidance for the Full-Year 2022
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 05
Evolus, Inc. Appoints Christos Monovoukas as Senior Vice President of Corporate Development Mar 03
Evolus, Inc. to Report Q4, 2021 Results on Mar 03, 2022 Feb 18
Evolus, Inc. Receives Acceptance of Submission in Australia, A Pivotal Step in Approval Process for Nuceiva Feb 09
Evolus, Inc. Provides Earnings Guidance for the Year 2022 Jan 27
Forecast to breakeven in 2024 Jan 01
Evolus, Inc. announced that it expects to receive $125 million in funding from Pharmakon Advisors, LP, BPCR Limited Partnership Dec 15
Third quarter 2021 earnings released: US$0.35 loss per share (vs US$0.34 loss in 3Q 2020) Nov 03
Forecast to breakeven in 2023 Sep 23
President recently sold €665k worth of stock Aug 20
Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.63 loss in 2Q 2020) Aug 06 Evolus, Inc.(NasdaqGM:EOLS) dropped from Russell Microcap Value Index
First quarter 2021 earnings released: EPS US$0.17 (vs US$0.58 loss in 1Q 2020) May 14
Full year 2020 earnings released: US$4.83 loss per share (vs US$3.19 loss in FY 2019) Mar 26
Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement Mar 25
New 90-day high: €11.51 Mar 04
Evolus, Inc. Announces Executive Changes Feb 27
Chief Commercial Officer has left the company Feb 27
Abbvie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation Feb 20
New 90-day high: €5.88 Feb 06
New 90-day high: €3.92 Jan 13
CEO報酬分析 Evolus の収益と比較して、David Moatazedi の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a -US$55m
Jun 30 2024 n/a n/a -US$53m
Mar 31 2024 n/a n/a -US$60m
Dec 31 2023 US$11m US$688k -US$62m
Sep 30 2023 n/a n/a -US$63m
Jun 30 2023 n/a n/a -US$66m
Mar 31 2023 n/a n/a -US$72m
Dec 31 2022 US$4m US$597k -US$74m
Sep 30 2022 n/a n/a -US$79m
Jun 30 2022 n/a n/a -US$79m
Mar 31 2022 n/a n/a -US$71m
Dec 31 2021 US$4m US$572k -US$47m
Sep 30 2021 n/a n/a -US$139m
Jun 30 2021 n/a n/a -US$131m
Mar 31 2021 n/a n/a -US$137m
Dec 31 2020 US$3m US$527k -US$163m
Sep 30 2020 n/a n/a -US$67m
Jun 30 2020 n/a n/a -US$82m
Mar 31 2020 n/a n/a -US$99m
Dec 31 2019 US$2m US$550k -US$90m
Sep 30 2019 n/a n/a -US$88m
Jun 30 2019 n/a n/a -US$73m
Mar 31 2019 n/a n/a -US$52m
Dec 31 2018 US$6m US$362k -US$47m
報酬と市場: Davidの 総報酬 ($USD 11.24M ) は、 German市場 ($USD 1.42M ) の同規模の企業の平均を上回っています。
報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者 Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 President 6.5yrs US$11.24m データなし Chief Financial Officer 2.2yrs US$2.46m 0.052% € 405.1k Chief Medical Officer and Head of Research & Development 10.8yrs US$2.93m 0.31% € 2.4m Head of Global Investor Relations & Corporate Communications less than a year データなし データなし General Counsel no data データなし データなし Vice President of Sales 6.1yrs データなし データなし Tomoko Yamagishi-Dressler Chief Marketing Officer 1.3yrs データなし 0.016% € 126.1k Senior Vice President of Human Resources 3yrs データなし データなし
もっと見る
経験豊富な経営陣: EVLの経営陣は 経験豊富 であると考えられます ( 3年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 President 6.5yrs US$11.24m データなし Independent Director 6.8yrs US$256.03k 0.043% € 339.8k Director 6.8yrs US$235.03k 0.86% € 6.7m Independent Director less than a year データなし データなし Chairman of the Board 6.8yrs US$271.03k 0.37% € 2.9m Independent Director 5.3yrs US$249.03k 0.049% € 386.0k Independent Director 2.8yrs US$222.03k 0.071% € 553.6k
もっと見る
経験豊富なボード: EVLの 取締役会 は 経験豊富 であると考えられます ( 6.5年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}